Co-Diagnostics JV, CoSara, to Participate at VIROCON 2025 in Pune, India

Core Insights - Co-Diagnostics, Inc. announced ongoing Phase II preclinical study data for its Co-Dx PCR MTB and HPV tests, supporting advancement to clinical performance testing [1][4] Group 1: Co-Dx PCR MTB Test - CoSara Diagnostics Pvt. Ltd. is supporting Phase II preclinical studies for the Co-Dx PCR MTB test, which evaluates Mycobacterium tuberculosis detection [2] - Phase I studies included 354 clinical specimens, while Phase II has evaluated 211 sputum specimens to establish concordance with other tests [2] Group 2: Co-Dx PCR HPV Test - The Phase I preclinical studies for the 8-type HPV multiplex test involved 286 clinical specimens to validate the Co-Primers® test chemistry [3] - Phase II has analyzed 53 specimens to facilitate the detection of three high-risk HPV genotypes, with ongoing refinement of the application algorithm [3] Group 3: Upcoming Events and Engagement - CoSara will host a booth at VIROCON 2025, providing an opportunity for attendees to learn more about the TB and HPV tests on the Co-Dx PCR platform [4] - VIROCON 2025 is organized by the India Council of Medical Research - National Institute of Virology, focusing on innovations in public health related to viral epidemics [5]